Rep. Neal P. Dunn

Maddy summaryThis bill requires Medicare Advantage plans to implement electronic prior authorization systems by 2027 and publish detailed data on their approval and denial rates for medical services by 2026. It directly affects Medicare Advantage plans (private insurers offering Medicare coverage) and their enrollees (seniors 65+), mandating transparency about prior authorization decisions, processing times, and appeal outcomes. Key provisions include requiring plans to report annual statistics on request approvals/denials, average processing times, and use of technology, with this data published publicly by the Centers for Medicare & Medicaid Services. The bill also sets timelines for plan responses to prior authorization requests and mandates reports to Congress on implementation and impacts.

Maddy summary# Summary of Tariff Suspensions and Reductions Document This document is a section of U.S. tariff legislation that adds new duty suspensions and reductions to the Harmonized Tariff Schedule of the United States. It contains 120 new tariff items (numbered 9902.19.01 through 9902.20.24) that provide temporary duty-free or reduced-duty status for various goods. Key features of the document: 1. **Content**: The list includes chemical compounds, food ingredients, and specialty materials (such as shelled pine nuts, licorice extract, refined carrageenan, various chemicals like neodymium metal, tungsten concentrate, and numerous organic compounds). 2. **Tariff Treatment**: Most entries are listed as "Free" (meaning duty-free), with a few having small duty rates (e.g., 0.7%, 1.8%, 2.3%, 2.9%, 4.3%). 3. **Effective Period**: All listed suspensions and reductions are effective "On or before 12/31/2025." 4. **Purpose**: These tariff suspensions are intended to support specific industries, reduce costs for manufacturers, or provide temporary relief for certain imported goods. 5. **Technical Details**: Each entry includes the chemical name, CAS number, Harmonized Tariff Schedule code, duty rate, and a brief description of the product. This document represents a legislative amendment to the Harmonized Tariff Schedule, specifically adding new subchapter II of chapter 99 to provide temporary duty relief for these specific items.

Maddy summaryThe Essential Caregivers Act of 2024 requires nursing homes and similar facilities to allow residents to designate essential caregivers who provide emotional support or assistance with daily activities. During emergencies when regular visitation is restricted, facilities must permit at least one essential caregiver access to residents daily and cannot deny access without following specific procedures. Facilities may deny access for a maximum of 7 days during emergencies (or 14 days with state approval), and must provide a written explanation and appeal process if access is denied. The bill establishes a 48-hour appeal process for residents and caregivers to challenge denials, with facilities required to prove violations during appeals. This law applies to Medicare skilled nursing facilities, Medicaid nursing facilities, intermediate care facilities, and certain inpatient rehabilitation facilities.

Maddy summaryHR 7997 amends the Trade Act of 1974 to automatically exclude goods from China under certain trade provisions. This means products from China would be subject to automatic exclusion from specific U.S. trade benefits without needing separate case-by-case reviews. The bill directly affects U.S. trade policies and import processes involving China by expanding an existing exclusion mechanism to specifically include China. The key provision adds "China" as a designated country triggering this automatic exclusion process.

Maddy summaryHR 7742, the At HOME Services Act, creates a 2-year Medicare demonstration program allowing hospitals to provide outpatient observation services to beneficiaries in their homes. It grants hospitals temporary exemptions from certain hospital requirements (like 24-hour on-site nursing and physical space standards) and expands telehealth access to home settings. Hospitals must maintain inpatient-level care standards, collect data on care quality and costs, and submit to a study comparing home-based care outcomes to traditional hospital care. The program will analyze factors like health outcomes, costs, patient experience, and demographic data before a final report is published.

Maddy summary# Summary of Proposed Legislation This document outlines a comprehensive U.S. legislative proposal with several key components: 1. **Research Restrictions**: - Requires certification from Federal research grant recipients that they are not Chinese citizens or participants in Chinese talent programs - Prohibits employment of Chinese nationals in federally funded research - Requires institutions receiving Federal assistance to agree not to knowingly employ individuals participating in Chinese talent programs 2. **Foreign Gifts and Contracts Disclosure**: - Mandates disclosure of foreign gifts/contracts over $50,000 to universities - Requires public reporting of restricted/conditional gifts/contracts - Creates a searchable public database of foreign gifts to universities - Requires institutions to maintain policies regarding foreign gifts to faculty and staff 3. **Investment Restrictions**: - Restricts tax-exempt organizations from holding investments in "disqualified Chinese companies" (defined as corporations incorporated in China or with significant Chinese government ownership) - Requires annual reporting on such investments - Allows limited waivers with public disclosure 4. **Taiwan Policy**: - Prohibits U.S. government from recognizing PRC claims to sovereignty over Taiwan without Taiwan's consent - Requires U.S. government to treat Taiwan's democratically elected government as the legitimate representative of the people of Taiwan - Requires a strategy to protect U.S. businesses from Chinese coercion efforts 5. **Additional Provisions**: - Requires participants in Chinese talent programs to register as agents of the Chinese government - Amends economic espionage laws to include education and research - Mandates disclosure of certain funds received by visa holders The legislation represents a significant effort to limit Chinese influence in U.S. academic institutions, research, and business sectors while establishing a more robust policy framework regarding Taiwan.

Maddy summaryThis bill changes the negotiation period for small-molecule drugs under the federal Drug Price Negotiation Program from 7 years to 11 years, matching the existing 11-year period for biologic drugs. It directly affects drug manufacturers participating in the program by extending the timeframe for price negotiations with the government. The amendment applies to all small-molecule drugs covered under the program, creating a uniform negotiation timeline for both drug types. The change takes effect as if included in the Inflation Reduction Act of 2022.

Maddy summaryHR 7142 (Alternatives to PAIN Act) requires Medicare Part D plans to cover non-opioid pain management drugs with no deductible and at the lowest copay level starting in 2025. It defines "qualifying non-opioid drugs" as FDA-approved medications that don’t act on opioid receptors (like certain NSAIDs or nerve pain treatments), excluding opioids and schedule I-III drugs. The bill prohibits Medicare plans from forcing patients to try opioids first (step therapy) or requiring prior approval for these non-opioid options. It directly affects Medicare beneficiaries needing pain management, especially those seeking alternatives to opioids for post-surgical or acute pain. The policy change aims to improve access to non-addictive pain treatments while preserving doctors' authority to prescribe medically appropriate care.

Maddy summaryThis bill, HR 6860, protects patients with end-stage kidney disease (ESRD) who require dialysis by preventing health insurance plans from discriminating against them. It amends Medicare rules to prohibit plans from treating dialysis coverage differently than other medical services based on a patient’s ESRD diagnosis, need for dialysis, or any other factor. The bill clarifies that plans can still choose which dialysis providers to include in their networks but cannot deny or limit coverage for dialysis services solely because of the patient’s condition. It ensures Medicare remains the secondary payer for these services as intended, without forcing plans to cover specific providers.

Maddy summaryHR 6790 establishes National Institutes of Health centers to advance research, early detection, and public awareness of rare kidney diseases, with a focus on rural and underserved communities. It mandates a federal study on genetic testing barriers, treatment patterns, and public awareness for rare kidney diseases affecting disproportionately impacted populations, including barriers to insurance coverage and access to specialists. The bill also funds nephrology training programs to increase specialists serving these communities and requires experiments to delay or prevent the need for dialysis and transplants. Total funding of $7 million is authorized for fiscal years 2024-2028 to support these research, education, and early intervention efforts.